NIHR Oxford Biomedical Research Centre

What NIHR Oxford Biomedical Research Centre does

NIHR Oxford Biomedical Research Centre is a translational research partnership jointly operated by the University of Oxford and Oxford University Hospitals NHS Foundation Trust, established in 2007 as one of the first five NIHR-funded Biomedical Research Centres. It runs 15 specialised research themes — including Cancer, Cardiovascular Medicine, Digital Health, Gene and Cell Therapy, Genomic Medicine, Imaging, Inflammation, Life-saving Vaccines, Microbiology, Neurology, Respiratory Medicine, Surgical Innovation, and Translational Data Science — supported by a NIHR Clinical Research Facility, a Health Economics Hub, a Medical Statistics Hub, an Ethics Group, a Training Hub, and a Patient and Public Involvement platform. The centre's outputs include the Oxford/AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19, ~3 billion doses deployed, ~6.3 million lives saved), the RECOVERY Trial (~47,000 participants across 187 NHS sites, four life-saving COVID-19 treatments identified), the world's first gene therapy for age-related macular degeneration, the first UK stem cell transplant for retinitis pigmentosa, the WHO-recommended R21 malaria vaccine, and the SEND digital vital signs monitoring system.

The underlying technology stack spans AI-based medical imaging (CariHeart for coronary risk, radiotranscriptomics, AI endoscopy and lung CT), photon-counting CT integrated with interventional imaging in the AMIIC centre, the ChAdOx adenoviral vaccine platform, advanced gene and cell therapy manufacturing, the Infections in Oxfordshire Research Database (IORD, ~1% of England's population), and large-scale federated data infrastructure. The Imaging theme has generated 13 patents and 7 spin-out companies over 10 years, and collaborations span 60+ companies. Strategic alliances include AstraZeneca, Janssen (J&J), Oracle (EIT Pathogena), VMIC, Genomics England, NICE, HRA, and HDR UK.

The business model is government grant-funded rather than commercial. Core revenue is the NIHR grant — currently £95.9m covering 1 December 2022 to 31 March 2028, drawn from a broader £816m NIHR allocation across 20 BRCs in England. Supplementary income comes from industry-funded trials, co-development agreements with pharma and SMEs, licensing through Oxford University Innovation, and grant income from charitable foundations. The centre does not charge patients and operates a community-led go-to-market focused on recruiting NHS sites and participants into trials, engaging industry partners for product development, and feeding evidence into NHS clinical pathways and WHO vaccine recommendations. The BRC is governed jointly by a Strategic Partnership Board and BRC Steering Committee, with Prof. Helen McShane (Director since August 2018) leading a small core operations team of approximately 27 staff.

Name

NIHR Oxford Biomedical Research Centre

Legal name

NIHR Biomedical Research Centre: Oxford

Website

https://oxfordbrc.nihr.ac.uk

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

NIHR Oxford Biomedical Research Centre is a government-funded translational research partnership between the University of Oxford and Oxford University Hospitals NHS Trust, operating across 15 research themes to convert scientific discoveries into NHS-applicable treatments, vaccines, gene therapies, and AI-driven diagnostics.

Ownership category

akta.pro rank

Product category

Translational Biomedical Research Services

NAICS

Other Scientific and Technical Consulting Services (541690), Testing Laboratories and Services (54138), Medical Laboratories (621511)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Services-General Medical & Surgical Hospitals, Nec (8062)

akta.pro primary industry

Electronic Data Capture (EDC) Platforms (HLACAOAA)

akta.pro secondary industries

National Public Health Reference Laboratories (HLAJAIAA), Regulatory Submissions & Clinical Content Management (eCTD/Publishing) (HLACAOAN)

Keywords

• Translational medical research
• Clinical trial infrastructure
• Biomedical research services
• Early-phase experimental medicine
• Health research partnership

Headquarters

HQ city

Oxford

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Others

Revenue model

1. Government research funding (NIHR): The BRC Oxford receives direct grant funding from the National Institute for Health and Care Research (NIHR). The current award runs from 1 December 2022 to 31 March 2028 with total funding of £95.9m. The NIHR awarded £816 million over five years to 20 BRCs across England. The BRC is part of OUH NHS Foundation Trust's research portfolio.
2. Industry partnerships and contract research: The Business Development team facilitates industry-supported research, fellowship schemes, and collaborative partnerships with pharma and SMEs. Revenue flows include industry-funded trials, co-development agreements, and licensing arrangements facilitated through Oxford University Innovation.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels12 records

Core offering

NIHR Oxford BRC is a translational research partnership between the University of Oxford and Oxford University Hospitals NHS Foundation Trust that conducts biomedical research across 15 specialised themes. It provides research infrastructure and support services for clinical trials, early-phase experimental medicine, ethics advisory, health economics, medical statistics, training, and digital health tools. Its outputs are treatments, diagnostics, vaccines, and medical technologies translated into NHS clinical practice and global health policy.

Product overview

NIHR Oxford Biomedical Research Centre is a research partnership between Oxford University Hospitals NHS Foundation Trust and the University of Oxford that conducts translational research across 15 specialized themes. The center offers a unified platform of research infrastructure services including the NIHR Clinical Research Facility for early-phase trials, Ethics Group, Health Economics Hub, Medical Statistics Hub, and Training Hub. Key products include the SEND Digital Monitoring System for digital patient records, and the Infections in Oxfordshire Research Database (IORD) for infection research. The center is structured around research themes covering Cancer, Cardiovascular Medicine, Digital Health, Gene and Cell Therapy, Genomic Medicine, Imaging, Inflammation, Vaccines, Metabolic Medicine, Microbiology, Musculoskeletal, Preventive Neurology, Respiratory Medicine, Surgical Innovation, and Translational Data Science, supported by Patient and Public Involvement services and Business Development partnerships.

Differentiator

Problem solved

Functional benefit

Products and services

• NIHR Oxford Clinical Research Facility
• BRC Oxford Ethics Group
• Health Economics Hub
• Medical Statistics Hub
• SEND Digital Monitoring System
• Infections in Oxfordshire Research Database (IORD)
• Training and Career Development Services (Training Hub)
• Patient and Public Involvement (PPI) Services
• Business Development and Industry Partnership Services

Quantifiable outcome

• 6.3 million lives estimated to have been saved by the Oxford/AstraZeneca COVID-19 vaccine
• +8 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability10 records

Feature7 records

Partnerships

13 partnerships are on record, tiered core and minor.

• University of OxfordcoreStrategic or Co-development Partner · 1 January 2007Primary academic partner of NIHR Oxford BRC. Provides research infrastructure, academic staff, laboratories, and translational research expertise across 15 themes. The partnership with OUH brings together academics and clinicians to translate scientific breakthroughs into potential new treatments, diagnostics and medical technologies.
• Oxford University Hospitals NHS Foundation TrustcoreStrategic or Co-development PartnerHost NHS Trust for the BRC Oxford. Provides clinical infrastructure, patient populations, and NHS governance framework. The joint governance structure between OUH and University of Oxford includes a Strategic Partnership Board and BRC Steering Committee to ensure optimal use of shared resources.
• Oxford Academic Health Partners (OAHP)coreStrategic or Co-development PartnerOAHP is an Academic Health Science Centre designation that strengthens and broadens the partnership between OUH and University of Oxford. It has unified senior leadership prioritising research for patient benefit and supports implementation of genomic medicine in clinical care pathways.
• Oxford Health NHS Foundation TrustminorStrategic or Co-development PartnerJoined the Joint Research Office (JRO) in 2022 expansion, alongside Oxford Brookes University, broadening the research partnership beyond the original OUH-University of Oxford structure.
• Oxford Brookes UniversityminorStrategic or Co-development PartnerJoined the Joint Research Office (JRO) in 2022 expansion, broadening the research partnership ecosystem.
• AstraZenecacoreStrategic or Co-development PartnerCo-developed the Oxford/AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19). The collaboration demonstrated BRC Oxford's ability to rapidly translate vaccine research into a globally deployed product, saving an estimated 6.3 million lives.
• University of BirminghamminorStrategic or Co-development PartnerPartnership through the Arthritis Therapy Acceleration Programme (A-TAP), which involves a collaboration with the University of Birmingham and a network of hospitals in the West Midlands for inflammatory disease research.
• Vaccine Manufacturing Innovation Centre (VMIC)minorStrategic or Co-development PartnerBRC Oxford is working with VMIC to support process development and technology transfer for larger-scale vaccine manufacturing, expanding capacity for early-phase vaccine trials beyond Oxford's in-house capabilities.
• National Institute for Health and Care Excellence (NICE)minorStrategic or Co-development PartnerBRC Ethics Group works with NICE to ensure that ethics is embedded in the biomedical research process. Health economics research directly informs NICE decision-making on adoption of new interventions and technologies into the NHS.
• Health Research Authority (HRA)minorStrategic or Co-development PartnerBRC Ethics Group works with HRA on proportionate governance for medical research. BRC ethics lead Mark Sheehan is a member of HRA's Ethics Review Advisory Group implementing changes to ethics review processes, including streamlined applications and modernised consent practices.
• Genomics EnglandminorStrategic or Co-development PartnerOxford plays a key role in the 100,000 Genomes Project and continues to contribute insights into rare diseases. Oxford is involved in Genomics England Clinical Interpretation Partnerships and the Genome Medicine Service Alliance.
• University of SheffieldminorStrategic or Co-development PartnerBurgeoning partnership with University of Sheffield in surgical research, providing access to a network of specialist researchers and addressing geographical variations in surgical co-morbidities.
• NHS Trusts across the UKminorStrategic or Co-development PartnerOxford has thriving partnerships with NHS Trusts across the UK to ensure research reaches populations who need it most and focuses on NHS priorities. The RECOVERY Trial operated across 187 sites and the BRC maintains active collaboration with NHS sites nationwide.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Market position

Strengths4 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/OxfordBRC
• YouTubeyoutube.com/user/OxfordBRC
• Facebookfacebook.com/oxfordbrc
• LinkedInlinkedin.com/company/nihr-oxford-biomedical-research-centre

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NIHR Oxford Biomedical Research Centre